IRIS
LAVATELLI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.392
AS - Asia 2.624
EU - Europa 2.023
SA - Sud America 317
AF - Africa 147
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.317
CN - Cina 1.136
SG - Singapore 642
IE - Irlanda 550
HK - Hong Kong 286
RU - Federazione Russa 261
DE - Germania 240
FI - Finlandia 239
VN - Vietnam 234
BR - Brasile 231
IT - Italia 180
FR - Francia 124
UA - Ucraina 118
ZA - Sudafrica 104
GB - Regno Unito 97
IN - India 86
SE - Svezia 42
JP - Giappone 40
CA - Canada 39
TR - Turchia 33
AR - Argentina 29
BD - Bangladesh 29
ES - Italia 29
IQ - Iraq 26
PL - Polonia 26
MX - Messico 25
NL - Olanda 20
PK - Pakistan 18
MA - Marocco 17
VE - Venezuela 16
AT - Austria 13
BE - Belgio 13
LT - Lituania 13
ID - Indonesia 12
CO - Colombia 11
EC - Ecuador 10
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 7
CL - Cile 6
KR - Corea 6
UY - Uruguay 6
AL - Albania 5
AU - Australia 5
AZ - Azerbaigian 5
EG - Egitto 5
ET - Etiopia 5
GR - Grecia 5
HU - Ungheria 5
MY - Malesia 5
PE - Perù 5
PT - Portogallo 5
UZ - Uzbekistan 5
IR - Iran 4
JM - Giamaica 4
JO - Giordania 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
BO - Bolivia 3
CH - Svizzera 3
DZ - Algeria 3
EE - Estonia 3
IL - Israele 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
RS - Serbia 3
TN - Tunisia 3
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MD - Moldavia 2
MN - Mongolia 2
NG - Nigeria 2
NP - Nepal 2
RO - Romania 2
AM - Armenia 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GH - Ghana 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
Totale 8.501
Salva come PNG Salva come JPEG
Città #
Dublin 550
Chandler 439
Singapore 362
Ashburn 330
San Jose 321
Dallas 304
Hong Kong 281
Beijing 272
Jacksonville 186
Nanjing 179
Helsinki 122
Boardman 112
Johannesburg 89
Los Angeles 89
Lauterbourg 84
Nanchang 84
Ho Chi Minh City 80
Princeton 80
Lawrence 77
Wilmington 72
Medford 71
Hanoi 62
Munich 62
New York 61
Shenyang 56
Hebei 55
Moscow 45
Jiaxing 44
Changsha 42
Buffalo 40
Shanghai 39
Ann Arbor 38
Hangzhou 38
Pavia 36
Tokyo 34
Tianjin 32
Redondo Beach 31
São Paulo 30
Santa Clara 29
Milan 26
Orem 25
Turku 23
Frankfurt am Main 20
Norwalk 20
Warsaw 20
Piscataway 18
Woodbridge 18
Ankara 17
Chennai 16
Montreal 16
London 15
Poplar 15
The Dalles 15
Boston 14
Chicago 14
Rio de Janeiro 14
Brussels 13
Council Bluffs 13
Denver 13
San Francisco 13
Atlanta 12
Avellino 12
Amsterdam 11
Brooklyn 11
Charlotte 11
Da Nang 11
Fairfield 11
Manchester 11
Seattle 11
Stockholm 11
Falkenstein 10
Haiphong 10
Mexico City 9
Washington 9
Catania 8
Chandigarh 8
Phoenix 8
Toronto 8
Baghdad 7
Caracas 7
Dhaka 7
Houston 7
Verona 7
Belo Horizonte 6
Biên Hòa 6
Campina Grande 6
Cape Town 6
Curitiba 6
Hải Dương 6
Jinan 6
Lahore 6
Ningbo 6
Nuremberg 6
Pune 6
Redwood City 6
Rome 6
Vienna 6
Addis Ababa 5
Guangzhou 5
Hyderabad 5
Totale 5.632
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 204
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 161
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 147
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 133
AMICA: an electronic patient record specifically designed for an amyloidosis network 129
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 128
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 128
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 127
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 122
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 122
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 119
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 118
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 118
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 118
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 115
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 114
A practical approach to the diagnosis of systemic amyloidoses 114
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 111
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 110
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 110
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 109
Biochemical markers in early diagnosis and management of systemic amyloidoses 108
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 106
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 105
AMICA: an electronic patient record specifically designed for an amyloidosis network. 105
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 105
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 105
Prognostication of survival and progression to dialysis in AA amyloidosis 105
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 104
A workflow management system for the biological samples exchange within the amyloidosis network 104
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 103
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 103
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 102
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 102
IceTrack: a biobank information management system maximizing flexibility and usability 101
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 100
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 100
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 98
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 98
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 98
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 98
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 97
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 96
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 94
A workflow management system for the biological samples exchange within the amyloidosis network 93
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 93
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 91
A case of monoclonal gammopathy of renal significance 91
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 90
Regulated expression of amyloidogenic immunoglobulin light chains in mice 89
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 89
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 87
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 87
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 86
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 81
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 81
A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils 81
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 80
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 80
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 79
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 78
Age-related amyloidosis outside the brain: A state-of-the-art review 78
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 78
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 77
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 76
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 74
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 73
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 72
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 72
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 72
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 71
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 71
Clinical proteomics for diagnosis and typing of systemic amyloidoses 71
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 68
Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features 67
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 67
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 64
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 60
The workings of the amyloid diseases. 58
AA-amyloidosis in cats (Felis catus) housed in shelters 57
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 57
Systemic amyloidoses and proteomics: The state of the art 56
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 55
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 53
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 53
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 52
Proteomics in protein misfolding diseases. 49
A practical approach to the diagnosis of systemic amyloidoses 45
How do we improve treatments for patients with amyloidosis using proteomics? 44
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 44
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 43
null 35
The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis? 29
null 28
Renal amyloid‐A amyloidosis in cats: Characterization of proteinuria and biomarker discovery, and associations with kidney histology 23
null 6
Totale 8.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.123
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202170 0 0 0 0 0 0 0 0 0 37 28 5
2021/2022308 2 5 2 4 6 2 6 39 20 3 38 181
2022/20231.410 181 116 18 82 120 121 10 59 623 8 32 40
2023/2024585 69 112 33 26 47 123 20 42 9 25 42 37
2024/20251.461 45 107 54 39 32 94 66 65 384 56 199 320
2025/20263.465 279 246 383 444 518 174 657 186 374 204 0 0
Totale 8.668